Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Steven Kyle Grinspoon, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Steven Grinspoon and Hang Lee.
Steven Grinspoon
Connection Strength
3.739
Hang Lee
  1. Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2021 Jan 23; 106(2):e520-e533.
    View in: PubMed
    Score: 0.247
  2. Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. J Infect Dis. 2020 08 17; 222(6):929-939.
    View in: PubMed
    Score: 0.239
  3. Association of In Utero HIV Exposure With Obesity and Reactive Airway Disease in HIV-Negative Adolescents and Young Adults. J Acquir Immune Defic Syndr. 2020 02 01; 83(2):126-134.
    View in: PubMed
    Score: 0.230
  4. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019 12; 6(12):e821-e830.
    View in: PubMed
    Score: 0.226
  5. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine. 2018 Sep; 35:58-66.
    View in: PubMed
    Score: 0.209
  6. Novel mediators of statin effects on plaque in HIV: a proteomics approach. AIDS. 2018 04 24; 32(7):867-876.
    View in: PubMed
    Score: 0.204
  7. Differential relationships of hepatic and epicardial fat to body composition in HIV. Physiol Rep. 2017 Oct; 5(19).
    View in: PubMed
    Score: 0.197
  8. Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection. JAMA Cardiol. 2016 07 01; 1(4):474-80.
    View in: PubMed
    Score: 0.180
  9. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial. J Clin Endocrinol Metab. 2016 Mar; 101(3):1123-33.
    View in: PubMed
    Score: 0.173
  10. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014 Sep 10; 28(14):2061-70.
    View in: PubMed
    Score: 0.159
  11. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014 Jul 23-30; 312(4):380-9.
    View in: PubMed
    Score: 0.156
  12. Effects of aging and smoking on carotid intima-media thickness in HIV-infection. AIDS. 2013 Jan 02; 27(1):49-57.
    View in: PubMed
    Score: 0.141
  13. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012 Dec; 97(12):4769-79.
    View in: PubMed
    Score: 0.138
  14. Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS. 2012 Mar 13; 26(5):587-97.
    View in: PubMed
    Score: 0.133
  15. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. . 2010 Dec 15; 55(5):615-9.
    View in: PubMed
    Score: 0.122
  16. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011 Jan; 96(1):E146-50.
    View in: PubMed
    Score: 0.121
  17. Effects of low-dose growth hormone withdrawal in patients with HIV. JAMA. 2010 Jul 21; 304(3):272-4.
    View in: PubMed
    Score: 0.119
  18. Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial. AIDS. 2009 May 15; 23(8):951-9.
    View in: PubMed
    Score: 0.110
  19. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA. 2008 Aug 06; 300(5):509-19.
    View in: PubMed
    Score: 0.104
  20. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008 Sep; 93(9):3499-504.
    View in: PubMed
    Score: 0.103
  21. Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS. 2007 Jul 31; 21(12):1591-600.
    View in: PubMed
    Score: 0.097
  22. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007 Jul; 92(7):2506-12.
    View in: PubMed
    Score: 0.095
  23. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab. 2006 Dec; 91(12):4916-24.
    View in: PubMed
    Score: 0.091
  24. Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial. J Clin Endocrinol Metab. 2018 11 01; 103(11):4176-4186.
    View in: PubMed
    Score: 0.053
  25. Aspartame Intake Relates to Coronary Plaque Burden and Inflammatory Indices in Human Immunodeficiency Virus. Open Forum Infect Dis. 2017; 4(2):ofx083.
    View in: PubMed
    Score: 0.048
  26. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. AIDS. 2016 Feb 20; 30(4):583-90.
    View in: PubMed
    Score: 0.044
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.